trending Market Intelligence /marketintelligence/en/news-insights/trending/njIv2qxG6PYQ9uaKRQvtdw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Perrigo settles patent litigation with Taro Pharmaceutical

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates

Blog

COVID-19 Impact & Recovery: Investment Banking


Perrigo settles patent litigation with Taro Pharmaceutical

Perrigo Co. plc settled a patent litigation with Taro Pharmaceutical Industries Ltd. for undisclosed terms.

The companies entered a dispute after Perrigo sought U.S. FDA approval to commercially market a generic version of Taro's Topicort spray.

The news is concurrent with the U.S. FDA's decision to approve Perrigo's generic version of Topicort.

The spray is indicated for the treatment of plaque psoriasis in patients 18 years or older. It had estimated sales of about $24 million for the 12 months ending November 2016.